Want to see LRMR full AI Analyst Report?
Top Page
Larimar Therapeutics
(NASDAQ:LRMR)
Select Model
Select Model
Rating:44Neutral
Price Target:
$2.50
▼(-40.05% Downside)
Action:Reiterated
Date:10/14/26
The score is primarily constrained by weak financial performance (no revenue, widening losses, and substantial cash burn) and very bearish technicals (price far below key moving averages with negative momentum). Corporate events provide a meaningful offset due to constructive regulatory and clinical progress and leadership strengthening, but valuation support is limited by negative earnings and no dividend.
Positive Factors
Regulatory and clinical progress
FDA alignment on a surrogate endpoint, rolling BLA acceptance, and planned Phase 3 initiation materially advance nomlabofusp toward potential approval. This reduces regulatory uncertainty relative to an earlier-stage program and creates a clearer development path for the company’s lead asset.
Negative Factors
No commercial revenue and widening losses
Larimar has no commercial revenue to offset its expanding research and development base, leaving financial performance dependent on future clinical and regulatory success. Widening losses increase the duration of pre-commercial risk and make earnings power difficult to establish over the next several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Regulatory and clinical progress
FDA alignment on a surrogate endpoint, rolling BLA acceptance, and planned Phase 3 initiation materially advance nomlabofusp toward potential approval. This reduces regulatory uncertainty relative to an earlier-stage program and creates a clearer development path for the company’s lead asset.
Read all positive factors
Larimar Therapeutics (LRMR) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$253.47M
Dividend YieldN/A
Average Volume (3M)1.62M
Price to Earnings (P/E)―
Beta (1Y)1.93
Revenue GrowthN/A
EPS Growth-27.00%
CountryUS
Employees71
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.99
Shares Outstanding103,882,935
10 Day Avg. Volume1,947,398
30 Day Avg. Volume1,619,083
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)3.56
Price to Sales (P/S)0.00
P/FCF Ratio-2.45
Enterprise Value/Market Cap0.66
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.97
Forecast
1Y Price Target
$16.33Price Target Upside291.69% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-1.37
Revenue Forecast (FY)N/A
Larimar Therapeutics Business Overview & Revenue Model
Company Description
Headquartered in Bala Cynwyd, Pennsylvania, Larimar Therapeutics, Inc. operates as a clinical-stage biotechnology firm. Its core mission involves crafting therapies for rare diseases, leveraging a distinctive cell-penetrating peptide technology pl...
Larimar Therapeutics Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
58
Neutral
Cash Flow
20
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -172.30M | -165.32M | -80.29M | -36.64M | -35.04M | -50.31M |
| Net Income | -172.60M | -165.67M | -80.60M | -36.95M | -35.35M | -50.64M |
Balance Sheet | ||||||
| Total Assets | 165.30M | 145.84M | 200.22M | 95.94M | 126.41M | 78.67M |
| Cash, Cash Equivalents and Short-Term Investments | 156.27M | 136.85M | 183.45M | 86.79M | 118.43M | 70.10M |
| Total Debt | 4.96M | 4.07M | 5.12M | 5.55M | 5.41M | 6.00M |
| Total Liabilities | 37.92M | 67.76M | 28.41M | 14.21M | 15.50M | 14.25M |
| Stockholders Equity | 127.38M | 78.08M | 171.81M | 81.72M | 110.90M | 64.41M |
Cash Flow | ||||||
| Free Cash Flow | -156.08M | -113.29M | -71.28M | -33.62M | -27.67M | -42.44M |
| Operating Cash Flow | -155.92M | -113.20M | -70.76M | -33.46M | -27.57M | -42.10M |
| Investing Cash Flow | 55.11M | 100.31M | -85.39M | 33.35M | -90.96M | 24.17M |
| Financing Cash Flow | 172.77M | 65.09M | 161.88M | 30.00K | 75.26M | 19.89M |
Larimar Therapeutics Technical Analysis
Negative
4.17
Price Trends
3.43
Negative
3.56
Negative
3.84
Negative
Market Momentum
-0.36
Negative
33.00
Neutral
56.88
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LRMR, the sentiment is Negative. The current price of 4.17 is above the 20-day moving average (MA) of 2.62, above the 50-day MA of 3.43, and above the 200-day MA of 3.84, indicating a bearish trend. The MACD of -0.36 indicates Negative momentum. The RSI at 33.00 is Neutral, neither overbought nor oversold. The STOCH value of 56.88 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for LRMR.
Larimar Therapeutics Risk Analysis
Larimar Therapeutics disclosed 85 risk factors in its most recent earnings report. Larimar Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 1 New Risks
1.
We initiated our rolling BLA submission to the FDA for marketing approval of nomlabofusp using the accelerated approval pathway and expect to submit the remaining modules in the second half of 2026; however, there can be no assurance that we will submit the remaining modules on our expected timeline, that the FDA will accept the BLA for filing or the FDA will approve our BLA submission for accelerated approval. Q2, 2026
Larimar Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | $1.20B | 8.51 | -109.40% | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $661.12M | -5.94 | -89.38% | ― | ― | -108.75% | |
45 Neutral | $242.46M | -0.87 | -84.95% | ― | 6.02% | -305.54% | |
45 Neutral | $87.37M | -0.34 | -242.28% | ― | ― | 21.31% | |
44 Neutral | $253.47M | -1.22 | -137.39% | ― | ― | -27.00% | |
42 Neutral | $119.36M | -2.06 | 72.64% | ― | 51.98% | 17.68% |
* Healthcare Sector Average
LRMR
Larimar Therapeutics
2.27
-1.68
-42.53%
OMER
Omeros
16.86
9.21
120.39%
VNDA
Vanda
4.05
-1.44
-26.23%
FHTX
Foghorn Therapeutics
2.01
-1.89
-48.46%
CADL
Candel Therapeutics
8.38
3.07
57.82%
NMRA
Neumora Therapeutics, Inc.
0.41
-1.91
-82.47%
Larimar Therapeutics Corporate Events
Business Operations and StrategyExecutive/Board Changes
Larimar Therapeutics Appoints New President and COO
Positive
Sep 29, 2026
On September 29, 2026, Larimar Therapeutics appointed John B. Harlow Jr. as president and chief operating officer under an employment agreement that includes a $560,000 base salary, performance-based bonus eligibility, and standard executive sever...
Business Operations and StrategyFinancial DisclosuresRegulatory Filings and Compliance
Larimar reports Q2 results and nomlabofusp progress
Positive
Aug 4, 2026
On August 4, 2026, Larimar Therapeutics reported its second-quarter 2026 financial and business results, highlighting progress in the development of its lead Friedreich’s ataxia candidate nomlabofusp. Longer-term open-label study data releas...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.